National Guideline Clearinghouse | Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer.

full-text ►

National Guideline Clearinghouse | Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer.



National Institute for Health and Care Excellence (NICE)

Guideline Title

Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer.

Bibliographic Source(s)

National Institute for Health and Care Excellence. Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer. London (UK): National Institute for Health and Care Excellence; 2014 Apr. 40 p. (Technology appraisal guidance; no. 310).

Guideline Status

This is the current release of the guideline.

This guideline meets NGC's 2013 (revised) inclusion criteria.